Takeda Pharmaceutical Co Ltd reports results for the quarter ended in September 30 - Earnings Summary

Reuters11-01
Takeda Pharmaceutical Co Ltd reports results for the quarter ended in September 30 - Earnings Summary
  • Takeda Pharmaceutical Co Ltd TAK.N reported quarterly adjusted earnings of JPY29.07​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of JPY-15.50. The mean expectation of two analysts for the quarter was for earnings of JPY87.45 per share. Wall Street expected results

  • Revenue rose 12.7% to $1.18 trillion from a year ago; analysts expected JPY1.08 trillion.

  • Takeda Pharmaceutical Co Ltd shares had fallen by 2.3% this quarter and lost 2.7% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts was unchanged in the last three months.​

  • In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Takeda Pharmaceutical Co Ltd is $16.30

This summary was machine generated from LSEG data November 1 at 02:59 a.m. UTC. ​All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Sep. 30 2024

87.45

29.07

Missed

30.36

33.80

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment